Adverse effect · Noopept (omberacetam)

How common is safety in humans with Noopept (omberacetam)?

D
Grade D — no human evidenceNo systematic international data · effect size: not measurable · adverse
Short answerNo human evidence. As of 10 September 2026, only no systematic international data exist for Noopept (omberacetam) for safety in humans. Reported as well tolerated in Russian use. No pharmacovigilance dataset outside Russia; no data on long-term use.

What the studies show

Reported as well tolerated in Russian use. No pharmacovigilance dataset outside Russia; no data on long-term use.

Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.

In context

Noopept is a synthetic molecule built from the dipeptide proline-glycine, developed at the Zakusov Institute in Moscow and registered in Russia as a nootropic for mild cognitive impairment after brain injury or stroke. Outside Russia it is not approved anywhere. The human evidence is a single Russian comparison against piracetam in patients with vascular or traumatic cognitive impairment; its English translation carries no abstract in PubMed, and no independent group has replicated it. The claims made for it in healthy people — focus, memory, learning — have never been tested in a controlled trial.

Noopept (omberacetam) is not approved (outside russia). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Noopept (omberacetam) proven to cause safety in humans?
No. There is no human evidence for it (No systematic international data); the claim rests on animal or cell studies and LYO grades it D.
What studies are behind the grade?
Reported as well tolerated in Russian use. No pharmacovigilance dataset outside Russia; no data on long-term use.
Is Noopept (omberacetam) approved for this?
No. Noopept (omberacetam) is not approved (outside Russia); it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Noopept (omberacetam)

Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →